RxDoctor Payments Data

Mohanakrishnan Sathyamoorthy, MD

Cardiovascular Disease · Fort Worth, TXNPI 1134233588

Payments from drug & device makers

$102,742in general payments, 2019–2025

Across 108 payments — averaging $951.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$74K
  • Artivion, Inc.$23K
  • Novartis$4K
  • Pfizer$262
  • E.r. Squibb & Sons, L.L.C.$242
  • Amarin Pharma, Inc.$221
  • plus $1K from 23 others
$1,169in research payments, 2019–2025

Across 2 payments — averaging $584.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Artivion, Inc.$1K

What the payments were for

  • Consulting fees$8,82830%
  • Speaking & faculty fees$13,65847%
  • Travel & lodging$3,62312%
  • Food & beverage$2,96910%
  • Education$530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$102,742 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$1,789,215
Medicare patients
1,182
Services billed
7,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban499$599,269
XareltoRivaroxaban203$216,586
EntrestoSacubitril/Valsartan189$191,015
MultaqDronedarone Hcl49$47,664
VascepaIcosapent Ethyl71$46,321
Repatha SureclickEvolocumab28$33,264
Ranolazine ErRanolazine273$26,619
JardianceEmpagliflozin28$22,833
CorlanorIvabradine Hcl24$18,049
Icosapent Ethyl35$17,528
NexletolBempedoic Acid15$14,748
Metoprolol Succinate862$10,466
Nifedipine ErNifedipine313$6,706
Rosuvastatin Calcium421$5,934
Repatha SyringeEvolocumab11$5,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$262$599,269499 claims
NovartisEntresto$4,180$191,015189 claims
Sanofi-aventis U.S. LLCMultaq$108$47,66449 claims
Boehringer IngelheimJardiance$38$22,83328 claims
AmgenCorlanor$182$18,04924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →